Head-to-head · WeighScore
Contour Health vs GoodRx
The verdict
GoodRx takes it — 69.6/100 to 66.8/100.
GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Contour Health | GoodRx |
|---|---|---|
| WeighScore | 66.8/100 | 69.6/100 |
| Grade | C | C |
| Scorecard rank | #177 | #116 |
| Semaglutide | $160/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $300/mo (starting dose, compounded) | $299/mo (brand Zepbound) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #177 · C
Strengths
- Free medical consultation — no charge to talk with a provider before starting
- Pay-per-vial pricing with no long-term subscription commitment required to participate
- Names its compounding pharmacy partner (Strive Pharmacy, 503A accredited) — a real transparency signal
- LegitScript badge links to a genuine, working LegitScript verification checker for the domain
- Board-certified Medical Director and named nurse-practitioner care team, not anonymous providers
Where it loses points
- State availability list is not published — Terms of Service only says "certain states"
- All product purchases are non-refundable per Terms of Service
- Compounded injectable only — no oral option, no brand-name Wegovy/Zepbound/Ozempic/Mounjaro
- Terms of Service also describe an optional subscription tier with a 3-month minimum, despite marketing emphasizing "no subscriptions"
- No insurance, Medicare, or Medicaid accepted — cash-pay or HSA/FSA only
Graded #116 · C
Strengths
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
Where it loses points
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.